Welcome to our dedicated page for Polypid Ltd. news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid Ltd. stock.
PolyPid Ltd. (Nasdaq: PYPD) is publicly described as a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, prolonged-release therapeutics. News about PolyPid often centers on the development and regulatory progress of its lead product candidate, D-PLEX100, and on milestones related to its proprietary PLEX (Polymer-Lipid Encapsulation matriX) drug delivery technology.
Investors and observers following PYPD news will find updates on clinical trial results, particularly from the Phase 3 SHIELD II trial of D-PLEX100 in abdominal colorectal surgeries. Company press releases report that this trial met its primary and key secondary endpoints and demonstrated reductions in surgical site infections and related outcomes when D-PLEX100 was added to standard of care.
Regulatory developments are another major theme in PolyPid’s news flow. The company has announced that D-PLEX100 received Breakthrough Therapy designation from the U.S. Food and Drug Administration and has reported positive pre-NDA meeting minutes supporting a New Drug Application submission. News items also describe the FDA’s agreement to a rolling NDA review, which PolyPid highlights as an important step in its regulatory strategy.
Corporate and operational updates appear regularly, including GMP inspection outcomes for the company’s manufacturing facility by the Israeli Ministry of Health, which PolyPid states support its readiness for potential commercial production. Additional news covers participation in medical and investor conferences, board and management changes such as the appointment of a new chairman of the board, and financial results reported via quarterly updates.
For readers tracking PYPD, this news stream provides insight into PolyPid’s clinical progress, regulatory interactions, manufacturing readiness and capital markets activity, all framed around its goal of improving surgical outcomes with prolonged-release therapeutics.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.
The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time.
Key highlights:
- Conference participants are advised to register 5 minutes before the call
- The company's core technology, PLEX (Polymer-Lipid Encapsulation matriX), enables controlled drug release over extended periods
- Their lead product, D-PLEX100, is in Phase 3 trials for preventing abdominal colorectal surgical site infections
- A preclinical candidate, OncoPLEX, is being tested for solid tumor treatment, starting with glioblastoma
The PLEX technology pairs with Active Pharmaceutical Ingredients (APIs) to deliver drugs at optimal release rates, ranging from days to months.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in The Citizens Life Sciences Conference in New York. The company's management will engage in a fireside chat on Wednesday, May 7, 2025, at 10:30 AM ET.
During the two-day conference, scheduled for May 7-8, 2025, the PolyPid management team will also be available for one-on-one investor meetings. Interested investors can arrange meetings through their Citizens JMP representatives.
PolyPid (Nasdaq: PYPD) has completed enrollment in the SHIELD II Phase 3 trial for D-PLEX₁₀₀, targeting the prevention of surgical site infections in abdominal colorectal surgery patients. The independent Data Safety Monitoring Board (DSMB) recommended concluding the study at 800 patients after analyzing unblinded efficacy data from the first 430 participants.
The company expects to report top-line results by Q2 2025, and if positive, plans to submit a New Drug Application (NDA) to the FDA. The submission will leverage the FDA's Fast Track and Breakthrough Therapy designations. PolyPid is currently engaged in discussions with potential partners for D-PLEX₁₀₀'s commercialization across various regions, with initial focus on the U.S. market.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 37th Annual ROTH Conference in Dana Point, California, scheduled for March 17-18, 2025.
The company will conduct a fireside chat, which will be available on-demand starting Monday, March 17, 2025, at 2:00 PM PT. Additionally, the management team will engage in one-on-one investor meetings during the event. Interested investors seeking meetings with PolyPid should coordinate through their ROTH representative.
PolyPid reported its Q4 and full-year 2024 financial results, highlighting significant progress in its SHIELD II Phase 3 trial of D-PLEX₁₀₀. The trial has enrolled over 700 patients, with completion expected in March 2025 and top-line results in Q2 2025. The DSMB recommended concluding the trial at 800 patients.
The company secured a private placement financing of $14.5 million, with potential additional proceeds of $27.0 million through warrants. Financial results showed R&D expenses of $7.0 million for Q4 2024 and $22.8 million for the full year. Net loss was $8.5 million for Q4 and $29.0 million for 2024. Cash position stood at $15.6 million as of December 31, 2024, expected to fund operations into Q3 2025.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual event is scheduled for February 11-12, 2025.
The company's presentation will be available on-demand starting Wednesday, February 12, 2025, at 11:20 AM Eastern Time and will remain accessible for 365 days through the conference platform. PolyPid's management team will also conduct one-on-one investor meetings during the event. Interested investors can arrange meetings through their Oppenheimer representative.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its fourth quarter and full-year 2024 financial results and operational highlights announcement for Wednesday, February 12, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. Management recommends participants register at least 5 minutes before the call starts. Those not planning to ask questions are advised to join via webcast.